Barclays assumed coverage on shares of Precision BioSciences (NASDAQ:DTIL) in a research note issued to investors on Monday, Marketbeat reports. The firm set an “overweight” rating and a $24.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 76.73% from the stock’s current price.

DTIL opened at $13.58 on Monday. Precision BioSciences has a 12 month low of $12.13 and a 12 month high of $19.00.

In other news, Director Global Strategic Fund Venbio bought 50,000 shares of the stock in a transaction on Monday, April 1st. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $800,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Tony Dung Ling Yao bought 6,487 shares of the stock in a transaction on Wednesday, April 3rd. The stock was purchased at an average price of $15.42 per share, for a total transaction of $100,029.54. The disclosure for this purchase can be found here.

Precision BioSciences Company Profile

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Read More: Google Finance

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with's FREE daily email newsletter.